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Abstract
Background
Despite the World Health Organization (WHO) regularly updating guidelines to recommend
earlier initiation of antiretroviral therapy (ART) in children, timely enrollment into care and ini-
tiation of ART in sub-Saharan Africa in children lags behind that of adults. The impact of
implementing increasingly less restrictive ART guidelines on ART initiation in Central Africa
has not been described.
Materials and Methods
Data are from the Central Africa International Epidemiologic Databases to Evaluate AIDS
(IeDEA) pediatric cohort of 3,426 children (0–15 years) entering HIV care at 15 sites in
Burundi, DRC, and Rwanda. Measures include CD4 count, WHO clinical stage, age, and
weight-for-age Z score (WAZ), each at enrollment into HIV care and at ART initiation.
Changes in the medians or proportions of each measure by year of enrollment and year of
ART initiation were assessed to capture potential impacts of changing ART guidelines.
Results
Median age at care enrollment decreased from 77.2 months in 2004–05 to 30.3 months in
2012–13. The median age at ART initiation (n = 2058) decreased from 83.0 months in
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2004–05 to 66.9 months in 2012–13. The proportion of children24 months of age at enroll-
ment increased from 12.7% in 2004–05 to 46.7% in 2012–13, and from 9.6% in 2004–05 to
24.2% in 2012–13 for ART initiation. The median CD4 count at enrollment into care
increased from 563 (IQR: 275, 901) in 2004–05 to 660 (IQR: 339, 1071) cells/μl in 2012–13,
and the median CD4 count at ART initiation increased from 310 (IQR:167, 600) in 2004–05
to 589 (IQR: 315, 1113) cells/μl in 2012–13. From 2004–05 to 2012–13, median WAZ
improved from -2 (IQR: -3.4, -1.1) to -1 (IQR: -2.5, -0.2) at enrollment in care and from -2
(IQR: -3.8, -1.6) to -1 (IQR: -2.6, -0.4) at ART initiation.
Discussion and Conclusion
Although HIV-infected children24 months of age accounted for half of all children enrolling
in care in our cohort during 2012–13, they represented less than a quarter of all those who
were initiated on ART during the same period. Further research is needed to identify barriers
to timely diagnosis, linkage to care, and initiation of ART among children with HIV infection.
Introduction
At the end of 2015, an estimated 1.8 million [1.5 million-2.0 million] children less than 15
years of age were living with HIV worldwide, 90% in sub-Saharan Africa [1]. More than 90%
of those children acquired their infection through mother-to-child transmission (MTCT) [1].
In the absence of ART, an estimated 26% of postnatally-infected and 52% of perinatally-
infected children would die in the first year of HIV infection [2]. Poor immunological, growth,
and neurodevelopmental outcomes are common in children who initiate ART at later stages of
the disease [3–8].
Access to ART has increased substantially in low- and middle-income countries, with the
greatest increase occurring in sub-Saharan Africa: from 100,000 people receiving ART in 2003
to 9.1 million in 2013 [1]. Along with this expansion in ART coverage, the World Health Orga-
nization (WHO) explicitly recommends ART initiation in i) all HIV infected children 1–10
years old living with HIV at any CD4 cell count or ii) as a priority among all children <2 years
old and those with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and
individuals with CD4% <25% (if <5 years old) or CD4 count350 cells/mm3 (if5 years
old), or iii) among all children <1 year old living with HIV irrespective of CD4 cell count [9,
10]. The impacts of the recommended changes on improved testing coverage (e.g., PMTCT
and identification of exposed infants), better infant diagnosis (e.g., PCR) and more impor-
tantly immediate initiation of ART among children in Central Africa has not been docu-
mented. Although the proportion of HIV-infected children receiving ART in sub-Saharan
Africa lags behind that of adults (23% of children vs. 37% of adults in 2013) [1], this disparity
is even greater in West and Central Africa, where just 13% of HIV-infected children vs. 32% of
adults were receiving ART in 2013 [1].
Only a few published studies have examined temporal trends in the characteristics of chil-
dren initiating ART in sub-Saharan Africa [11–15]. Although these studies showed a decline
over time in disease severity at ART initiation, a substantial proportion of infants and children
were still initiating ART at an advanced disease stage [11–13]. To improve timely HIV diagno-
sis and ART initiation, and to reduce morbidity and mortality among HIV-infected children
in resource-constrained settings, it is important to understand the characteristics of children
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enrolling in care and initiating ART and how these have changed over time as provision of
prevention of mother-to-child transmission (improved identification of HIV-exposed infants),
early infant diagnosis and testing capacity (e.g., DNA PCR) improves, and HIV treatment
guidelines expand in Central Africa. Knowledge of these characteristics will facilitate efforts to
identify challenges with timely HIV diagnosis and ART initiation. We thus assessed temporal
trends in the characteristics of HIV-infected children at enrollment in HIV care (a proxy for
time of diagnosis) and at time of ART initiation from 2004 to 2013 in three Central African
countries: Burundi, the Democratic Republic of Congo (DRC), and Rwanda.
Materials and Methods
Study setting and participants
We analyzed data on pediatric patients aged 0–15 years from Burundi, the DRC and Rwanda
participating in the Central Africa International Epidemiologic Databases to Evaluate AIDS
(CA-IeDEA). CA-IeDEA is a multi-country project that collects secondary data from patients
receiving HIV care and treatment in the Central African region. The two clinics in the DRC,
ten in Rwanda, and three in Burundi that contributed data have been previously described
[16–18]. In each participating clinic, data were collected using standardized clinical paper
forms that were regularly entered into electronic databases. HIV infection was generally diag-
nosed by serological testing in children older than 18 months and by virological testing in chil-
dren younger than 18 months. Children confirmed as HIV-infected by serological or
virological testing who were 0–15 years of age at HIV care enrollment between 2004 and 2013
were included in this analysis.
Variables and statistical analysis
The main variables of interest were CD4 cell count, WHO clinical stage, age, and weight-for-
age Z score (WAZ). CD4 count, WAZ and WHO clinical stage at enrollment into care were
defined as the measurement taken at or closest to (not later than six months before or after)
the enrollment date if no measures were taken on the date of enrollment. CD4 cell counts and
WAZ at ART initiation were defined as the measurement taken at ART initiation (i.e. not ear-
lier than 6 months before or later than 3 months after). WAZ was calculated using 2006 WHO
standards [19] for children 10 years or younger and Centers for Disease Control and Preven-
tion standards for children older than 10 years [20]. Other continuous variables were catego-
rized as follows: CD4 count (<200, 200–450, >450 cells/μl), and age (0–24, 25–60, 61–84, 85–
120, and 121–156 months). Year of enrollment and year of ART initiation were grouped as
2004–05, 2006–07, 2008–09, 2010–11, and 2012–13 to reflect temporal changes in WHO
guidelines over time.
Demographic characteristics (age and sex) and HIV-associated characteristics (CD4 count,
WHO stage, and WAZ score) at care enrollment and ART initiation were analyzed. Descrip-
tive statistics (numbers and percentages for categorical variables, and median and interquartile
range (IQR) for continuous variables) were calculated. Chi-square and Kruskal-Wallis tests
were used to examine changes in distributions over the 10-year period.
Ethical approval for the study was granted by the Albert Einstein College of Medicine Insti-
tutional Review Board in New York, and by the relevant ethics review boards in Rwanda
(National Health Research Committee and National Ethics Committee), Burundi (Comite
National d’ Ethique) and DRC (Ministère de l’enseignement supe´rieur et universitaire, Univer-
site´ de Kinshasa E´cole de sante´ publique). Data for the Central Africa International Epidemio-
logic Database to Evaluate AIDS (CA-IeDEA) is publicly available upon request as part of the
global IeDEA consortium.
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Results
Table 1 shows characteristics of children when they enrolled into care (n = 3426) and at ART
initiation (n = 2058). Overall, from 2004–13, the median age at enrollment was 58.2 months
(interquartile range (IQR); 19.8, 102) and 70.3 (IQR; 29.2, 113) at ART initiation. Nearly equal
proportions of boys and girls enrolled in care, and initiated ART over the 10-year period.
The median time from enrollment in care to ART initiation for the different age groups are:
1.3 for 0–24 and 25–60 months, 2.1 for 61–84 months, 3.1 for 85–120 months and 2.4 for 121–
Table 1. Characteristics of children at enrollment in care and at ART initiation in the Central Africa
IeDEA Cohort, 2004–2013.
Enrollment ART Initiation
n = 3426 (%) n = 2058 (%)
Age (months) (n, %)
Median (IQR) 58.2 (19.8; 102) 70.3 (29.2; 113)
0–24 982 (28.7) 422 (20.5)
25–60 775 (22.6) 497 (24.1)
61–84 489 (14.3) 267 (13.0)
85–120 626 (18.3) 439 (21.3)
121–156 554 (16.2) 433 (21.0)
Sex (n, %)
Male 1669 (48.7) 1047 (50.9)
Female 1757 (51.3 1011 (49.1)
Country (n, %)
Burundi 722 (21.1) 299 (14.5)
DRC 1307 (38.1) 1002 (48.7)
Rwanda 1397 (40.8) 757 (36.8)
CD4 Count (n, %)
Median (IQR) 648 (339; 1029) 457 (249; 936)
<200 309 (14.2) 325 (19.6)
200–450 429 (19.7) 493 (29.7)
>450 1440 (66.1) 842 (50.7)
WHO Clinical Stage (n, %)
No Data 1185 (34.6) 335 (16.3)
I 611 (17.8) 310 (15.1)
II 625 (18.2) 411 (20.0)
III 901 (26.3) 903 (43.9)
IV 104 (3.0) 99 (4.8)
Weight-for-age Z-score
Median (IQR) -1.8 (-3.0;-0.7) -1.9 (-3.0; -0.8)
>-2 1276 (55.1) 922 (52.9)
-3 to -2 455 (19.8) 377 (21.6)
<3 585 (25.3) 445 (25.5)
Year (n, %)
2004–05 630 (18.4) 280 (13.6)
2006–07 680 (19.8) 431 (20.9)
2008–09 697 (20.3) 413 (20.1)
2010–11 729 (21.3) 468 (22.7)
2012–13 690 (20.1) 466 (22.6)
doi:10.1371/journal.pone.0169871.t001
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156 months. The median CD4 count was 648 cells/μl (IQR; 339, 1029) at enrollment into care
and 457 cells/μl (IQR; 249, 936) at ART initiation. WHO clinical staging data were not avail-
able for more than one-third of children at care enrollment and for about 16% of children at
ART initiation. Over one-third of children with WHO staging data were classified as stage III
or IV when they enrolled into care, with nearly half (48%) of these classified as stage III or IV
at ART initiation. Median WAZ was -1 (IQR; -3.0, -0.7) at care enrollment and -1 (IQR; -3.0,
0.8) at ART initiation. Overall, children24 months of age were 29% of those enrolled in care
and 21% of those initiated on ART.
Table 2 reports children’s characteristics by year of enrollment into care. Median age at
enrollment fell from 77.2 months in 2004–05 to 30.3 months in 2012–13 (p =<0.0001). The
proportion of children24 months of age who enrolled in care increased from 13% in 2004–
05 to 47% in 2012–13. Median CD4 count at enrollment in care increased from 563 in 2004–
05 to 660 cells/μl in 2012–13 (p =<0.0001). The proportion of children with CD4 count<200
cells/μl and 200–349 cells/μl also declined from 2004–05 to 2012–13 but remained fairly stable
among those whose CD4 count is>350–499 cells/μl and >500 cells/μl. Median CD4 count
increased marginally in all age groups, with the highest increase among children 0–24 months
(p = 0.04) and lowest among those aged 121–156 months (p = 0.26). The proportion of chil-
dren classified as stage III or IV at enrollment decreased from 37% in 2004–05 to 20% in
2012–13. Median WAZ was -2 in 2004–05 and -1 in 2012–13 (p = <0.0001).
Characteristics of children at care enrollment by country are shown in Tables 3–5. In
Burundi, the median age decreased from 53.5 months in 2008–09 to 33.0 months in 2010–11,
and then increased to 49.7 months in 2012–13. In the DRC, a similar trend was observed with
the median age decreasing from 76.8 months in 2004–05 to 40.7 months in 2012–13. However,
in Rwanda, though the median age in 2004–05 and 2006–07 was similar to that observed in
DRC, it decreased continuously to 11.4 months in 2012–13. The proportion of children24
months of age mostly drove the decreasing trend in median age at enrollment across countries.
Between 2010–11 and 2012–13, this proportion more than doubled from 32.3% to 66.1% in
Rwanda, changed slightly in DRC (from 35.0% to 37.7%), but decreased in Burundi, from 43%
to 36%.
The proportion of children with WHO staging data who were classified as stage III or IV at
enrollment in care in Burundi was 30%, 25% and 36% in 2008–09, 2010–11, and 2012–13,
respectively. In the DRC, the proportion of children classified as stage III or IV was 64% in
2004–05 and decreased continuously to 20% in 2012–13, whereas the proportion in Rwanda
decreased from a peak of 19% in 2006–2007 to 16% in 2008–09, 9.3% in 2010–11, and 3.4% in
2012–13. Nearly equal proportions of boys and girls enrolled in care in each country from
2004–13. Median WAZ increased progressively from 2004–13 in the DRC and Rwanda, but
fluctuated in Burundi from 2008–09 to 2012–13.
Table 6 shows children’s characteristics at ART initiation by year, from 2004 to 2013. The
median age at ART initiation was 83.0 months in 2004–05, progressively decreased until
2010–11 to a median of 49.2 months, and then rose to 67.2 months in 2012–13 (p = <0.0001).
The proportion of ART initiators24 months of age increased from 9.6% in 2004–05 to a
peak of 29.2% in 2010–11, before declining to 24.2% in 2012–13. During the same period, the
median CD4 count increased from 310 cells/μl in 2004–05 to 589 cells/μl in 2012–13 (p =
<0.0001). The proportion of children with median CD4 count<200 at ART initiation
decreased from 32% in 2004–05 to 13% in 2012–13 whereas it fluctuated or remained fairly
stable among children with >200 cells/μl. Median CD4 count at ART initiation increased
among all age groups from 2004–05 to 2012–13, with the most significant increase observed
among children aged 25–60 months (p = 0.0003).
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Table 2. Characteristics of children in the Central Africa IeDEA cohort by year of enrollment.
2004–05 2006–07 2008–09 2010–11 2012–13 p-value
n = 630 (%) n = 680 (%) n = 697 (%) n = 729 (%) n = 690 (%)
Age (months) (n, %)
Median (IQR) 77.2(44.8,110) 74.5(35.6,111) 53.8(21.0,98.0) 40.5(12.3,90.7) 30.3(5.9,87.6) <0.0001
0–24 80 (12.7) 114 (16.8) 195 (28.0) 272 (37.3) 321 (46.5) <0.0001
25–60 151 (24.0) 157 (23.1) 178 (25.5) 165 (22.6) 124 (18.0)
61–84 126 (20.0) 118 (17.4) 98 (14.1) 83 (11.4) 64 (9.3)
85–120 155 (24.6) 155 (22.8) 119 (17.1) 108 (14.8) 89 (12.9)
121–156 118 (18.7) 136 (20.0) 107 (15.4) 101 (13.9) 92 (13.3)
Sex (n,%)
Male 291 (46.2) 337 (49.6) 360 (51.6) 344 (47.2) 337 (48.8) 0.3
Female 339 (53.8) 343 (50.4) 337 (48.4) 385 (52.8) 353 (51.2)
Country (n,%)
Burundi NA NA 194 (27.8) 277 (38.0) 251 (36.4) <0.0001
DRC 268 (42.5) 256 (37.6) 289 (41.5) 291 (39.9) 203 (29.4)
Rwanda 362 (57.5) 424 (62.4) 214 (30.7) 161 (22.1) 236 (34.2)
CD4 count (n, %)
Missing Data (Not in p-value) 93 (14.8) 91 (13.4) 282 (40.5) 330 (45.3) 452 (65.5) <0.0001
Overall Median (IQR) 563(275,901) 670(361,1056) 675(349,1104) 695(398,1084) 660(339,1071) 0.001
<200 96 (17.9) 75 (12.7) 56 (13.5) 53 (13.3) 29 (12.2)
200–349 81 (15.1) 63 (10.7) 48 (11.6) 31 (7.8) 31 (13.0)
>350–499 64 (11.9) 82 (13.9) 45 (10.8) 47 (11.8) 20 (8.4)
>500 296 (55.1) 369 (62.6) 266 (64.1) 268 (67.2) 158 (66.4)
Median CD4 count by age (IQR)
0–24 month 995 (542, 1629) 1240 (923, 2009 1176 (675, 1912) 1066 (667, 1695) 1012 (672, 1664) 0.04
25–60 months 778 (395, 1040) 760 (491, 1207) 842 (475, 1137) 779 (527, 1224) 851 (596, 1161) 0.55
61–84 months 555 (338, 832) 685 (351, 1003) 635 (276, 974) 633 (397, 920) 671 (439, 857) 0.61
85–120 months 424 (201, 669) 480 (277, 828) 500 (270, 823) 499 (247, 840) 441 (214, 686) 0.41
121–156 months 331 (181, 577) 397 (235, 692) 366 (169, 612) 370 (108, 704) 505 (298, 871) 0.26
n for 0–24 months 63 92 89 102 46
n for 25–60 months 129 144 113 108 56
n for 61–84 months 112 105 68 56 33
n for 85–120 months 134 135 74 65 50
n for 121–156 months 99 113 71 68 53
WHO clinical stage (n,%)
Missing data (Not in p-value) 233 (37.0) 260 (38.2) 215 (30.8) 240 (32.9) 237 (34.4) <0.0001
I 57 (9.0) 70 (10.3) 129 (18.5) 152 (20.9) 203 (29.4)
II 108 (17.1) 135 (19.9) 130 (18.6) 140 (19.2) 112 (16.2)
III 206 (32.7) 200 (29.4) 200 (28.7) 172 (23.6) 123 (17.8)
IV 26 (4.1) 15 (2.2) 23 (3.3) 25 (3.4) 15 (2.2)
Weight-for-age Z-score (n,%)
Missing data (Not in p-value) 220 (34.9) 255 (37.5) 178 (25.5) 235 (32.2) 222 (32.2)
Median (IQR) -2.2(-3.4,-1.1) -1.9(-3.2,-0.8) -1.6 (-2.9–0.6) -1.7(-3.1,-0.5) -1.4(-2.5,-0.2) <0.0001
>-2 181 (44.1) 220 (51.8) 299 (57.6) 277 (56.1) 299 (63.9) <0.0001
-3 to -2 106 (25.9) 79 (18.6) 98 (18.9) 84 (17.0) 88 (18.8)
<-3 123 (30.0) 126 (29.6) 122 (23.5) 133 (26.9) 81 (17.3)
doi:10.1371/journal.pone.0169871.t002
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The overall proportion of children without WHO clinical staging data declined from 24%
in 2004–05 to about 13% in 2012–13. Among children with WHO staging data reported, the
proportion of those classified as stage III or IV decreased from 54% 2004–05 to 42% to 2012–
13 (p = <0.0001). There was improvement in the median WAZ, from -2 in 2004–05 to -1 in
2012–13 (p =<0.0001).
Table 3. Characteristics at enrollment in care of children in Central Africa IeDEA in Burundi by year of enrollment.
2004–05
(n, %)
2006–07
(n,%)
2008–09
n = 194 (%)
2010–11
n = 277 (%)
2012–13
n = 251 (%)
p-Value
Age (months)(n,%)
Median (IQR) 53.5 (18.5, 98.4) 33.0 (8.1, 93.5) 49.7 (11.6, 97.4) 0.19
0–24 55 (28.3) 118 (42.6) 90 (35.9) 0.17
25–60 51 (26.3) 53 (19.1) 50 (19.9)
61–84 23 (11.9) 27 (9.6) 27 (10.8)
85–120 35 (18.0) 40 (14.4) 42 (16.7)
121–156 30 (15.5) 39 (14.1) 42 (16.7)
Sex (n,%)
Male 99 (51.0) 123 (44.4) 118 (47.0) 0.36
Female 95 (49.0) 154 (55.6) 133 (53.0)
CD4 count (n,%)
Missing Data (Not in P-value) 152 (78.4) 217 (78.34) 187 (74.5)
Median (Q1,Q3) 712(512,1124) 562(347,988) 698(418,978) 0.25
<200 5 (11.9) 8 (13.3) 4 (6.3) 0.03
200–349 7 (11.7) 7 (10.9)
350–499 4 (9.5) 11 (18.3) 6 (9.4)
>500 33 (78.6) 34 (56.7) 47 (73.4)
Median CD4 for 0–24 months 1092(750, 2010) 828(491,1427) 1143(518,1978) 0.61
Median CD4 for 25–60 months 987(536,1299) 843(386,1375) 943(618,1818) 0.64
Median CD4 for 61–84 months 640(525,754) 446(315,985) 597(504,809) 0.76
Median CD4 for 85–120 months 911(599,1178) 513(379,619) 582(312,775) 0.14
Median CD4 for 121–156 months 497(279,638) 342(151,577) 616(408,924) 0.06
n for 0–24 months 4 15 10
n for 25–60 months 12 17 11
n for 61–84 months 9 6 11
n for 85–120 months 9 8 16
n for 121–156 months 8 14 16
WHO clinical stage (n,%)
Missing Data (Not in P-value) 92 (47.4) 147 (53.1) 56 (22.3)
Stage I 19 (18.6) 21 (16.2) 58 (29.7) 0.047
Stage II 24 (23.5) 41 (31.5) 47 (24.1)
Stage III 46 (45.1) 55 (42.3) 77 (39.5)
Stage IV 13 (12.7) 13 (10.0) 13 (6.7)
Weight-for-age Z-score (n,%)
Missing Data (Not in P-value) 97 (50.0) 160 (57.8) 57 (22.7)
Median (Q1, Q3) -1.4(-2.3,-0.2) -1.6(-3.4,-0.2) -1.3(-2.5,0.3) 0.077
>-2 67 (69.1) 68 (58.1) 123 (63.4) 0.035
-3 to -2 10 (10.3) 15 (12.8) 38 (19.6)
<-3 20 (20.6) 34 (29.1) 33 (17.0)
doi:10.1371/journal.pone.0169871.t003
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Tables 7–9 depict children’s characteristics at ART initiation in each country. In Burundi,
the median age was 71.4 months in 2008–09 but remained fairly stable from 2010–13. The pro-
portion of children24 months of age who initiated ART from 2008–09 to 2012–13 increased
from 11% to 16%. In the DRC, the median age remained stable at ~75 months between 2004–
07 then declined to 40.2 months in 2010–11 before rising to 59.9 months in 2012–13. The pro-
portion of ART initiators24 months of age increased from 11.5% in 2004–05 to 33% in
Table 4. Characteristics at enrollment in care of children in Central Africa IeDEA in DRC by year of enrollment.
2004–05
n = 268 (%)
2006–07
n = 256 (%)
2008–09
n = 289 (%)
2010–11
n = 291 (%)
2012–13
n = 203 (%)
p-Value
Age (months) (n,%)
Median (IQR) 76.8 (43.3, 114) 66.1(29.8,103) 49.8 (16.3, 85.1) 42.4(15.4,86.8) 40.7(8.2,96.6) <0.0001
0–24 35 (13.1) 53 (20.7) 96 (33.3) 102 (35.1) 75 (36.9) <0.0001
25–60 68 (25.4) 66 (25.8) 74 (25.0) 75 (25.8) 49 (24.1)
61–84 52 (19.4) 42 (16.4) 41 (14.2) 38 (13.1) 21 (10.3)
85–120 61 (22.8) 51 (19.9) 42 (14.5) 43 (14.8) 28 (13.8)
121–156 52 (19.4) 44 (17.2) 33 (11.0) 33 (11.3) 30 (14.8)
Sex (n,%)
Male 123 (45.9) 125 (48.8) 144 (49.8) 149 (51.2) 105 (51.7) 0.7
Female 145 (54.1) 131 (51.2) 145 (50.2) 142 (48.8) 98 (48.3)
CD4 count (n,%)
Missing Data (Not in P-value) 11 (4.1) 17 (6.6) 90 (31.1) 62 (21.3) 102 (50.3)
Median (Q1,Q3) 543(253,852) 631(273,1076) 618(293,1011) 656(364,1066) 610(316,1017) 0.09
<200 53 (20.6) 46 (19.2) 36 (18.1) 40 (17.5) 15 (14.9) 0.32
200–349 31 (12.1) 20 (8.4) 26 (13.1) 16 (7.0) 13 (12.9)
350–499 38 (14.8) 29 (12.1) 21 (10.6) 27 (11.8) 9 (8.9)
>500 135 (52.5) 144 (60.3) 116 (58.3) 146 (63.8) 64 (63.4)
Median CD4 for 0–24 months 1191(706,1757) 1204(765,1846) 1029(616,1912) 1066(576,1670) 1133(672,1292) 0.8
Median CD4 for 25–60 months 607(275,942) 668(451,1096) 719(359,988) 759(448,1057) 640(511,1017) 0.44
Median CD4 for 61–84 months 495(331,802) 668(199,976) 389(116,900) 618(438,855) 680(386,1285) 0.22
Median CD4 for 85–120 months 431(188,649) 442(249,907) 377(195,627) 387(130,642) 431(252,612) 0.68
Median CD4 for 121–156 months 317(133,577) 257(49,585) 295(100,579) 151(25,442) 365(113,547) 0.17
n for 0–24 months 35 48 56 68 18
n for 25–60 months 63 64 58 64 31
n for 61–84 months 52 41 31 34 12
n for 85–120 months 57 48 26 35 19
n for 121–156 months 50 38 28 28 21
WHO clinical stage (n,%)
Missing Data (Not in P-value) 3 (1.1) 14 (5.5) 22 (7.6) 10 (3.4) 12 (5.9)
Stage I 29 (10.9) 40 (16.5) 71 (26.6) 83 (29.5) 109 (57.1) <0.0001
Stage II 65 (24.5) 71 (29.3) 68 (25.5) 84 (29.9) 42 (22.0)
Stage III 151 (57.0) 119 (49.2) 122 (45.7) 106 (37.7) 39 (20.4)
Stage IV 20 (7.5) 12 (5.0) 6 (2.2) 8 (2.8) 1 (0.5)
Weight-for-age Z-score(n,%)
Missing Data (Not in P-value) 3 (1.1) 3 (1.2) 2 (0.7) 1 (0.3) 5 (2.5)
Median (Q1, Q3) -2.4(-3.6,-1.3) -2.1(-3.3,-1.0) -1.9(-3.2,-0.7) -2.1(-3.3,-0.9) -1.4(-2.7,-0.5) <0.0001
>-2 106 (40.0) 119 (47.0) 147 (51.2) 141 (48.6) 127 (64.1) 0.0003
-3 to -2 69 (26.0) 51 (20.2) 60 (20.9) 58 (20.0) 32 (16.2)
<-3 90 (34.0) 83 (32.8) 80 (27.9) 91 (31.4) 39 (19.7)
doi:10.1371/journal.pone.0169871.t004
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2010–11, before dropping to 24% in 2012–13. In Rwanda, the median age at ART initiation
declined from 90.2 months in 2004–05 to 44.8 months in 2012–13, driven by the increasing
proportion of children24 months of age, which rose from 7% to 35% over the same period.
The median CD4 count increased by about 200 and 300 cells/μl in the DRC and Rwanda
respectively between 2004–05 and 2012–13, and by more than 100 cells/μl in Burundi from
2008–09 to 2012–13. The proportion of children classified as WHO clinical stage III or IV in
Table 5. Characteristics at enrollment in care of children in Central Africa IeDEA in Rwanda by year of enrollment.
2004–05
n = 362 (%)
2006–07
n = 424 (%)
2008–09
n = 214 (%)
2010–11
n = 161 (%)
2012–13
n = 236 (%)
p-Value
Age (months) (n,%)
Median (IQR) 77.6 (45.6, 109) 78.4 (41.0, 116) 68.5 (27.7, 109) 50.7 (15.2, 97.0) 11.4 (2.2, 49.7) <0.0001
0–24 45 (12.4) 61 (14.4) 44 (20.6) 52 (32.3) 156 (66.1) <0.0001
25–60 83 (22.9) 91 (21.5) 53 (24.8) 37 (23.0) 25 (10.6)
61–84 74 (20.4) 76 (17.9) 34 (15.9) 18 (11.2) 16 (6.8)
85–120 94 (26.0) 104 (24.5) 42 (19.6) 25 (15.5) 19 (8.0)
121–156 66 (18.2) 92 (21.1) 41 (19.2) 29 (18.0) 20 (8.5)
Sex (n,%)
Male 168 (46.4) 212 (50.0) 117 (54.7) 72 (44.7) 114 (48.3) 0.28
Female 194 (53.6) 212 (50.0) 97 (45.3) 89 (55.3) 122 (51.7)
CD4 count (n,%)
Missing Data (Not in P-value) 82 (22.7) 74 (17.5) 40 (18.7) 51 (31.7) 163 (69.1) <0.0001
Median (Q1,Q3) 582(298,927) 681(377,1026) 736(376,1159) 801(598,1213) 741(301,1123) 0.0005
<200 43 (15.4) 29 (8.3) 15 (8.6) 5 (4.5) 10 (13.7)
200–349 50 (17.9) 43 (12.3) 22 (12.6) 8 (7.3) 11 (15.1)
350–499 26 (9.3) 53 (5.1) 20 (11.5) 9 (8.2) 5 (6.8)
>500 161 (57.5) 225 (64.3) 117 (67.2) 88 (80.0) 47 (64.4)
Median CD4 for 0–24 months 800(259,1411) 1344(1014,2143) 1305(1106,1912) 1240(965,1971) 951(698,1559) 0.0075
Median CD4 for 25–60 months 882(548,1199) 855(555,1254) 999(620,1213) 1000(665,1335) 983(696,1216) 0.5746
Median CD4 for 61–84 months 648(390,934) 695(399,1016) 760(476,1266) 738(400,1017) 709(387,981) 0.6195
Median CD4 for 85–120 months 378(212,727) 498(307,744) 461(302,819) 856(499,1117) 305(135,938) 0.0066
Median CD4 for 121–156 months 345(224,568) 460(273,755) 385(254,612) 675(362,796) 586(301,1132) 0.0415
n for 0–24 months 28 44 29 19 18
n for 25–60 months 66 80 43 27 14
n for 61–84 months 60 64 28 16 10
n for 85–120 months 77 87 39 22 15
n for 121–156 months 49 75 35 26 16
WHO clinical stage (n,%)
Missing Data (Not in P-value) 230 (63.5) 246 (58.0) 101 (47.2) 83 51.6) 169 (71.6)
Stage I 28 (21.2) 30 (16.9) 39 (34.5) 48 (61.5) 36 (53.7) 0.0001
Stage II 43 (32.6) 64 (36.0) 38 (33.6) 15 (19.2) 23 (34.3)
Stage III 55 (41.7) 81 (45.5) 32 (28.3) 11 (14.1) 7 (10.4)
Stage IV 6 (4.5) 3 (1.7) 4 (3.5) 4 (5.1) 1 (1.5)
Weight-for-age Z-score (n,%)
Missing Data (Not in P-value) 217 (59.9) 252 (59.4) 79 (36.9) 74 (46.0) 160 (67.8)
Median (IQR) -1.8(-2.9,-0.9) -1.7(-3.0,-0.6) -1.4(-2.4,-0.6) -0.9(-1.7,-0.1) -1.6(-2.3,-0.4) 0.001
>-2 75 (51.7) 101 (58.7) 85 (63.0) 68 (78.2) 49 (64.5) 0.002
-3 to -2 37 (25.5) 28 (16.3) 28 (20.7) 11 (12.6) 18 (23.7)
<-3 33 (22.8) 43 (25.0) 22 (16.3) 8 (9.2) 9 (11.8)
doi:10.1371/journal.pone.0169871.t005
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Table 6. Characteristics of children in the Central Africa IeDEA cohort by year of ART initiation.
2004–05
n = 280 (%)
2006–07
n = 431 (%)
2008–09
n = 413 (%)
2010–11
n = 468 (%)
2012–13
n = 466 (%)
p-value
Age (months) (n, %)
Median (IQR) 83.0 (49.8, 117) 79.3 (38.5, 117) 71.3 (27.8, 112) 49.9(21.7,106) 67.2(25.2,115) <0.0001
0–24 27 (9.6) 65 (15.1) 87 (21.1) 133 (28.42) 110 (23.6) <0.0001
25–60 66 (23.6) 102 (23.7) 94 (22.8) 127 (27.14) 108 (23.2)
61–84 52 (18.6) 63 (14.3) 55 (13.3) 45 (9.62) 52 (11.2)
85–120 73 (26.1) 103 (23.9) 94 (22.8) 79 (16.8) 90 (19.3)
121–156 62 (22.1) 98 (22.7) 83 (20.1) 84 (17.95) 106 (22.7)
Sex (n,%)
Male 136 (48.6) 227 (52.7) 220 (53.3) 239 (51.07%) 230 (49.4) 0.73
Female 144 (51.4) 204 (47.3) 193 (46.3) 229 (48.93%) 236 (50.6)
Country (n,%)
Burundi N/A N/A 28 (6.8) 63 (13.5) 208 (44.6) <0.0001
DRC 165 (58.9) 227 (52.7) 214 (51.8) 265 (56.6) 131 (28.1)
Rwanda 115 (41.1) 204 (47.3) 171 (41.4) 140 (29.9) 127 (27.2)
CD4 count (n, %)
Missing Data (Not in p-value) 23 (8.2) 29 (6.7) 71 (17.2) 90 (19.2) 185 (39.7)
Median (IQR) 310 (167, 600) 471 (228, 950) 437 (246, 879) 560 (317,1066) 589 (315,1113)
<200 83 (32.3) 85 (21.1) 62 (18.1) 58 (15.3) 37 (13.17) <0.0001
200–349 62 (24.1) 73 (18.2) 84 (24.6) 57 (15.1) 58 (20.6) <0.0001
350–499 35 (13.6) 54 (13.4) 39 (11.4) 57 (15.1) 32 (11.4)
>500 77 (30.0) 190 (47.3) 157 (45.9) 206 (54.5) 154 (54.1)
Median by age group (IQR)
0–24 months 883 (611, 1291) 1140 (832, 1784) 1073 (684, 1784) 1158 (705, 1796) 1267 (845, 2141) 0.06
25–60 months 469 (240, 838) 628 (425, 1029) 726 (360, 1042) 703 (435, 1151) _889 (610, 1358) 0.0003
61–84 months 332 (178, 482) 544 (264, 867) 432 (227, 697) 546 (329, 684) 597 (329, 655) 0.01
85–120 months 219 (120, 378) 339 (204, 615) 302 (214, 419) 327 (174, 462) 338 (217, 655) 0.003
121–156 months 223 (109, 321) 249 (131, 424) 267 (169, 358) 315 (97, 428) 342 (246, 470) 0.01
n for 0–24 months 27 62 66 102 60
n for 25–60 months 58 94 79 102 57
n for 61–84 months 49 61 47 38 33
n for 85–120 months 67 95 81 64 63
n for 121–156 months 56 90 69 72 68
WHO clinical stage (n,%)
Missing data (Not in p-value) 68 (24.3) 71 (16.5) 70 (16.9) 64 (13.68%) 62 (13.3)
I 17 (6.1) 45 (10.4) 58 (14.0) 81 (17.31%) 109 (23.4) <0.0001
II 40 (14.3) 91 (21.1) 88 (21.3) 93 (19.87%) 99 (21.2)
III 136 (48.6) 206 (47.8) 183 (44.3) 199 (42.52%) 179 (38.4)
IV 19 (6.8) 18 (4.2) 14 (3.4) 31 (6.62%) 17 (3.6)
Weight-for-age Z-score (n, %)
Missing data (Not in p-value) 71 88 60 62 33
Median (IQR) -2.6 (-3.8, -1.6) -2.0 (-3.2, 0.9) -2.0 (-.3.0, -0.9) -1.8(-3.0,-0.7) -1.5(-2.6,-0.4) <0.0001
>-2 70 (33.5) 176 (51.3) 181 (51.3) 221 (54.4) 274 (63.3) <0.0001
-3 to -2 53 (25.4) 70 (20.4) 83 (23.5) 85 (20.9) 86 (19.9)
<-3 86 (41.1) 97 (28.3) 89 (25.2) 100 (24.6) 73 (16.9)
doi:10.1371/journal.pone.0169871.t006
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each country was noteworthy. Nearly half and slightly more than half of children in Burundi
and the DRC, respectively, and nearly one-third of children in Rwanda were classified as stage
III or IV. Considerable proportions of children in the three countries were underweight at
ART initiation, although these proportions continuously declined from 2004-05-2012-13.
Fig 1 depicts the trend in the proportion of children initiated on ART within three months
of their enrollment in care. Before 2006, 34% of children were initiated on ART within three
Table 7. Characteristics at ART initiation of children in Central Africa IeDEA in Burundi by year of ART initiation.
2004–05
(n, %)
2006–07
(n, %)
2008–09
n = 28 (%)
2010–11
n = 63 (%)
2012–13
n = 208 (%)
p-Value
Age (months) (n,%)
Median (IQR) 71.4 (41.0, 124) 80.4 (32.6, 123) 79.1 (35.9, 123) 0.97
0–24 3 (10.7) 10 (15.9) 34 (16.3) 0.89
25–60 8 (28.6) 18 (28.6) 48 (23.1)
61–84 5 (17.9) 7 (11.1) 27 (13.0)
85–120 3 (10.7) 11 (17.5) 43 (20.7)
121–156 9 (32.1) 17 (27.0) 56 (26.9)
Sex (n,%)
Male 16 (57.1) 34 (54.0) 102 (49.0) 0.62
Female 12 (42.9) 29 (46.0) 106 (51.0)
CD4 count (n,%)
Missing Data (Not in P-value) 20 (71.4) 31 (49.2) 130 (62.5)
Median (Q1,Q3) 519(168,662) 383(215,599) 644(376,1080) 0.002
<200 3 (37.5) 7 (21.9) 7 (9.0) 0.013
200–349 5 (15.6) 9 (11.5)
350–499 11 (34.4) 16 (20.5)
>500 5 (62.5) 9 (28.1) 46 (59.0)
Median CD4 for 0–24 months 623(447,828) 565(293,1934) 0.8383
Median CD4 for 25–60 months 632(163,1100) 419(358,637) 736(618,1190) 0.1797
Median CD4 for 61–84 months 603(511,695) 333(264,392) 840(418,1225) 0.0882
Median CD4 for 85–120 months 526(526,526) 389(155,493) 644(411,1190) 0.033
Median CD4 for 121–156 months 173(151,629) 325(132,575) 416(343,780) 0.2182
n for 0–24 months 3 8
n for 25–60 months 2 8 13
n for 61–84 months 2 4 13
n for 85–120 months 1 7 22
n for 121–156 months 3 10 22
WHO clinical stage (n,%)
Missing Data (Not in P-value) 16 (57.1) 21 (33.3) 17 (8.2)
Stage I 1 (2.38) 27 (14.1) 0.049
Stage II 8 (19.05) 33 (17.3)
Stage III 10 (83.3) 32 (76.19) 116 (60.7)
Stage IV 2 (16.7) 1 (2.38) 15 (7.9)
Weight-for-age Z-score(n,%)
Missing Data (Not in P-value) 18 (64.3) 30 (47.6) 16 (7.7)
Median (Q1, Q3) -1.0(-1.6,-0.6) -2.3(-3.2,-1.3) -1.5(-2.7,-0.4) 0.07
>-2 9 (90.0) 16 (48.5) 120 (62.5) 0.16
-3 to -2 1 (10.0) 7 (21.2) 35 (18.2)
<-3 10 (30.3) 37 (19.3)
doi:10.1371/journal.pone.0169871.t007
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months of their enrollment into care. The proportion increased slightly to 40% in 2006–07 but
remained fairly stable from 2008–13 at about one-third of children who enrolled in care. In
Fig 2, we show the median age at enrollment into care in all countries from 2004-05-2012-13.
Overall, age at enrollment into care continually declined in all countries until 2010–11. After
2011, age at enrollment increased in Burundi, plateaued in the DRC and continued to decline
in Rwanda. As shown in Fig 3, overall median age at ART initiation declined until 2010–2011
Table 8. Characteristics at ART initiation of children in Central Africa IeDEA in the DRC by year of ART initiation.
2004–05
n = 165 (%)
2006–07
n = 227 (%)
2008–09
n = 214 (%)
2010–11
n = 265 (%)
2012–13
n = 131 (%)
p-Value
Age (months) (n,%)
Median (IQR) 74.8 (45.6, 109) 74.9 (35.9, 113) 54.3 (21.9, 96.4) 40.2(18.5,84.4) 59.9(25.2,111) <0.0001
0–24 19 (11.5) 36 (15.9) 61 (28.5) 87 (32.8) 31 (23.7) <0.0001
25–60 44 (26.7) 57 (25.2) 54 (25.2) 83 (31.3) 35 (26.7)
61–84 31 (18.8) 37 (16.3) 30 (14.0) 26 (9.8) 14 (10.7)
85–120 38 (23.0) 47 (20.7) 43 (20.1) 34 (12.8) 25 (19.1)
121–156 33 (20.0) 50 (22.0) 26 (12.1) 35 (13.2) 26 (19.8)
Sex (n,%)
Male 80 (48.5) 108 (47.6) 110 (51.4) 136 (51.3) 67 (51.1) 0.9
Female 85 (51.5) 119 (52.4) 104 (48.6) 129 (48.7) 64 (48.9)
CD4 count (n,%)
Missing Data (Not in P-value) 8 (4.9) 8 (3.5) 36 (16.8) 42 (15.9) 29 (22.1)
Median (Q1,Q3) 359(162,675) 552(218,1015) 545(233,911) 656(317,1109) 547(278,963) <0.0001
<200 48 (30.6) 50 (22.8) 39 (21.9) 40 (17.9) 18 (17.7) 0.0002
200–349 29 (18.5) 26 (11.9) 26 (14.6) 24 (10.8) 21 (20.6)
350–499 22 (14.0) 30 (13.7) 21 (11.8) 26 (11.7) 9 (8.8)
>500 58 (36.9) 113 (51.6) 92 (51.7) 133 (59.6) 54 (52.9)
Median CD4 for 0–24 months 838(667,1282) 1108(757,1827) 888(655,1430) 1117(667,1774) 1237(845,2047) 0.1543
Median CD4 for 25–60 months 443(215,892) 630(389,1061) 708(347,984) 758(428,1067) 640(511,1029) 0.152
Median CD4 for 61–84 months 335(189,574) 667(125,931) 378(211,697) 591(349,737) 439(319,601) 0.2452
Median CD4 for 85–120 months 224(68.0,491) 456(233,866) 266(158,533) 267(102,474) 262(87.0,337) 0.0902
Median CD4 for 121–156 months 237(116,377) 236(60.0,438) 169(41.0,484) 115(28.0,360) 310(133,370) 0.4592
n for 0–24 months 19 35 45 71 24
n for 25–60 months 39 57 48 71 25
n for 61–84 months 30 37 26 22 9
n for 85–120 months 36 44 36 28 20
n for 121–156 months 33 46 23 31 24
WHO clinical stage (n,%)
Missing Data (Not in P-value) 1 (0.8) <0.0001
Stage I 9 (5.5) 28 (12.3) 25 (11.7) 49 (18.5) 41 (31.5)
Stage II 27 (16.4) 60 (26.4) 62 (29.0) 62 (23.4) 41 (31.5)
Stage III 115 (69.7) 126 (55.5) 123 (57.5) 134 (50.6) 47 (36.2)
Stage IV 14 (8.5) 13 (5.7) 4 (1.9) 20 (7.6) 1 (0.8)
Weight-for-age Z-score(n,%)
Missing Data (Not in P-value) 1 (0.44) 1 (0.47)
Median (Q1, Q3) -2.6(-3.9,-1.6) -2.0(-3.2,-0.9) -2.1(-3.2,-1.1) -2.0(-3.2,-0.8) -1.7(-2.7,-0.6) <0.0001
>-2 58 (35.15) 116 (51.33) 101 (47.42) 132 (49.81) 78 (59.54) 0.0006
-3 to -2 36 (21.82) 44 (19.47) 50 (23.47) 57 (21.51) 30 (22.90)
<-3 71 (43.03) 66 (29.20) 62 (29.11) 76 (28.68) 23 (17.56)
doi:10.1371/journal.pone.0169871.t008
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and then rose slightly in 2012–2013. In Fig 4, we show the median time from enrollment in
care to ART initiation among initiators by age group.
Discussion
Early HIV diagnosis, enrollment in care, and ART initiation are critical to halt the rapid pro-
gression of HIV disease and reduce mortality in HIV-infected children [21]. Our study
Table 9. Characteristics at ART initiation of children in Central Africa IeDEA in Rwanda by year of ART.
2004–05
n = 115 (%)
2006–07
n = 204 (%)
2008–09
n = 171 (%)
2010–11
n = 140 (%)
2012–13
n = 127 (%)
p-Value
Age (months) (n,%)
Median (IQR) 90.2 (56.1, 120) 89.2 (42.0, 119) 90.7 (47.1, 123) 71.3 (23.4, 116) 44.8 (12.7, 105) <0.0001
0–24 8 (7.0) 29 (14.2) 23 (13.4) 36 (25.7) 45 (35.4) <0.0001
25–60 22 (19.1) 45 (22.1) 32 (18.7) 26 (18.6) 25 (19.7)
61–84 21 (18.3) 26 (12.7) 20 (11.7) 12 (8.6) 11 (8.7)
85–120 35 (30.4) 56 (27.4) 48 (28.1) 34 (24.3) 22 (17.3)
121–156 29 (25.2) 48 (23.5) 48 (28.1) 32 (22.9) 24 (18.9)
Sex (n,%)
Male 56 (48.7) 114 (55.9) 94 (55.0) 69 (49.3) 61 (48.0) 0.47
Female 59 (51.3) 90 (44.1) 77 (45.0) 71 (50.7) 66 (52.0)
CD4 count (n,%)
Missing Data (Not in P-value) 15 (13.0) 21 (10.3) 15 (8.8) 17 (12.1) 26 (20.5)
Median (Q1,Q3) 263(167,441) 385(234,821) 350(264,779) 526(324,1033) 579(305,1310) <0.0001
<200 35 (35.00) 35 (19.13) 20 (12.82) 11 (8.94) 12 (11.88) <0.0001
200–349 33 (33.00) 47 (25.68) 58 (37.18) 28 (22.76) 28 (27.72)
350–499 13 (13.00) 24 (13.11) 18 (11.54) 20 (16.26) 7 (6.93)
>500 19 (19.00) 77 (42.08) 60 (38.46) 64 (52.03) 54 (53.47)
Median CD4 for 0–24 months 1087(233,1332) 1146(993,1784) 1207(1106,1854) 1479(894,1983) 1504(1010,2219) 0.3412
Median CD4 for 25–60 months 469(262,698) 625(452,874) 749(458,1064) 1113(634,1532) 1275(782,2178) 0.0001
Median CD4 for 61–84 months 325(167,441) 500(280,751) 447(282,698) 548(381,694) 481(251,801) 0.236
Median CD4 for 85–120 months 212(124,314) 295(167,407) 304(238,362) 355(295,433) 332(205,369) 0.0034
Median CD4 for 121–156 months 216(98.0,293) 252(183,381) 283(236,352) 336(254,536) 334(282,391) 0.0041
n for 0–24 months 8 27 21 28 28
n for 25–60 months 19 37 29 23 19
n for 61–84 months 19 24 19 12 11
n for 85–120 months 31 51 44 29 21
n for 121–156 months 23 44 43 31 22
WHO clinical stage (n,%)
Missing Data (Not in P-value) 68 (59.1) 71 (34.8) 54 (31.6) 43 (30.7) 44 (34.7) <0.0001
Stage I 8 (17.0) 17 (12.8) 33 (28.2) 31 (32.0) 41 (49.4)
Stage II 13 (27.7) 31 (23.3) 26 (22.2) 23 (23.7) 25 (30.1)
Stage III 21 (44.7) 80 (60.2) 50 (42.7) 33 (34.0) 16 (19.3)
Stage IV 5 (10.6) 5 (3.8) 8 (6.8) 10 (10.3) 1 (1.2)
Weight-for-age Z-score(n,%)
Missing Data (Not in P-value) 71 (61.7) 87 (42.7) 41 (24.0) 32 (22.9) 17 (13.4) <0.0001
Median (Q1, Q3) -2.6(-3.3,-1.7) -2.0(-3.1,-0.9) -1.8(-2.6,-0.7) -1.3(-2.4,-0.5) -1.3(-2.3,-0.2) <0.0001
>-2 12 (27.3) 60 (51.3) 71 (54.6) 73 (67.6) 76 (69.1)
-3 to -2 17 (38.6) 26 (22.2) 32 (24.6) 21 (19.4) 21 (19.1)
<-3 15 (34.1) 31 (26.5) 27 (20.8) 14 (13.0) 13 (11.8)
doi:10.1371/journal.pone.0169871.t009
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describes trends in characteristics of children enrolling in HIV care and initiating ART
between 2004 and 2013 in the three Central African countries of Burundi, the DRC, and
Rwanda to assess whether changes in the characteristics of children reflect changes in WHO
guidelines for progressively earlier ART initiation.
Our results show that in all three countries the median age at enrollment in care (a proxy
for HIV diagnosis) substantially decreased from 2004 to 2013, driven mainly by the increasing
Fig 1. Proportion of children initiating ART within 3 months.
doi:10.1371/journal.pone.0169871.g001
Fig 2. Median age at enrollment in HIV care.
doi:10.1371/journal.pone.0169871.g002
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proportion of children24 months of age, with a substantial increase observed in Rwanda
and smaller increases in the DRC and Burundi. In Rwanda, for example, this increase reflects
expanded access to DNA PCR for early infant diagnosis (EID) and the resulting increase in
population coverage of EID from 28% to 72% from 2008–2011 after the country integrated
EID with vaccination programs and invested in a robust mobile phone reporting system [22].
It is equally likely that increases in Rwanda reflect the effectiveness of the country’s ART pro-
gram, considered one of the most effective for adults in the world also applies to children due
to the availability of resources through PEPFAR, the Global Fund and others.
Along with the increasing proportion of children who were24 months of age at enroll-
ment, the median CD4 count at entry into care also increased over time from 563 in 2004–05
to 660 cells/μl in 2012–13, with similar increases in median CD4 count at ART initiation (310
in 2004–05 to 589 cells/μl in 2012–13). Further, the median CD4 count for all age groups
increased at both enrolment into care and at ART initiation from 2004-05-2012-13 as shown
in Tables 2 and 3. These results suggest that children 0–24 months and those 25–60 months
Fig 3. Median age at ART initiation.
doi:10.1371/journal.pone.0169871.g003
Fig 4. Median time from enrollment in care to ART initiation by age group.
doi:10.1371/journal.pone.0169871.g004
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were enrolling in care or initiating ART with higher CD4 cell counts compared with older chil-
dren who enrolled in care or initiated ART with lower CD4 cell counts.
The likelihood of rapid progression of HIV disease and death among perinatally-infected
children, and the evidence that early initiation of ART substantially reduces morbidity and
mortality [8] led to the WHO’s 2010 recommendation for ART in all children <12 months
regardless of CD4 count or clinical stage [9]. Our results show a significant decrease (p =
<0.0001) in the median age at both enrollment in care and at ART initiation. Although some
progress can be inferred on the basis of the results presented here, for example the falling
median age at enrollment and ART initiation, there remains a substantial gap between the
proportions of children<24 months who enrolled in care and those who initiated ART. None-
theless, based on our analysis, we believe that the increase in CD4 count is due to children
enrolling at younger ages versus being less sick at enrollment in care.
With regard to the number of children initiating ART, we observed that the number of chil-
dren initiating ART in our sample is lower than those reported by Tene, et. al. [28] among chil-
dren in Rwanda. The lower number of children initiating ART in our sample may be due to
the selection of the clinics in our sample, which may not adequately represent the general pop-
ulation of pediatric HIV cohort, especially in Rwanda or may in fact reflect the proportion of
children who are likely deceased or were lost to follow up and therefore unable to initiate ART.
While this lack of representative sample is a limitation of our study, the findings presented are
nonetheless critically important to highlight how changing guidelines are impacting on enroll-
ment in care and initiation of ART among pediatric cohort in the sites where we obtained
data.
While in-depth analyses are needed to fully understand the reasons for this gap, it is likely
due to numerous structural factors, including time between sample collection and return of
DNA PCR results, which is done centrally in all countries. Similarly, recent evidence from
Zimbabwe showed that the lack of training in pediatric HIV among primary care providers is
a strong barrier to successful implementation of comprehensive quality HIV service for chil-
dren in extremely resource-poor settings like Central Africa [23]
The proportion of children without WHO staging data at both enrollment in care and ART
initiation declined over time, it is plausible but hard to know how this could have biased our
findings and/or in what direction although our focus in reporting the lack of WHO staging
data was to highlight the importance of WHO staging in determining at what stage of disease
classification children were enrolling in care or initiating ART. We note this as a limitation of
the study.
Malnutrition, weight loss and failure to thrive are important clinical features in children
presenting with AIDS and have been identified as causes of morbidity and mortality [24, 25].
Consistent with these studies [24–27], our median WAZ results suggest that many children in
the cohort are either moderately or severely underweight, an indication of advanced disease,
especially in the DRC where over half of children who enrolled in care through 2010–11 have a
WAZ <-2. Again, this suggests that children who are considerably underweight when they
enrolled in care or initiated ART may be presenting with advanced stages of the disease.
To our knowledge, this is the first study in Central Africa that combines data from 3 coun-
tries to examine trends in demographic and clinical characteristics of children at HIV care
enrollment and at ART initiation. A strength of our analysis is that it included Rwanda, a
country with robust data at the forefront of scaling HIV services and high retention rates
among pediatric HIV patients [28], as well as Burundi and the DRC, two countries that consis-
tently lag behind in pediatric HIV treatment and from which there are limited data. It is worth
noting the different sample sizes, characteristics and non-representativeness of selected clinics
in our sample. The participating clinics in CA-IeDEA countries are not a representative
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sample of clinics from those countries, and may include those with more technical capacity. In
addition, our analyses are purely descriptive and in the absence of any strong evidence, it is dif-
ficult to attribute causation or to any other outcomes such as loss to follow up, death and trans-
fers or to state categorically that the changes we observed are in response to policy changes.
We have only recently begun to collect data on these outcomes, thus a limitation of our analy-
sis is the inability to explore causal relationships behind the observed trends or directly test the
effect of changing guidelines. Nevertheless, it seems highly plausible that the changes we
observed may be a response to changes in guidelines even though other factors, such as
increased donor funding and health system response to pediatric HIV care may have contrib-
uted to the observed changes. It is worth stating that in-depth analyses are needed to identify
barriers to timely HIV diagnosis, enrollment into care, and ART initiation among children in
the region. This is critical because Central and West Africa have the highest under five mortal-
ity worldwide [29], and further analyses are needed to examine the trends in outcomes (lost-
to-follow-up, mortality) among HIV-infected children enrolled in care in this region.
Conclusion
The proportion of children 24 months of age or younger at enrollment into HIV care in
CA-IeDEA participating clinics has increased since 2004. However, this increase has not fully
translated into early initiation of ART. Further analyses are needed to identify barriers to
timely initiation of ART among children in HIV care.
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